Isotope-Labeled Compounds

Isotope-labeled compounds are chemical substances in which some atoms in their molecules are replaced by isotope atoms. The range of stable isotope products can cover from gases to complex molecules. Isotope-labeled compounds could provide a site-specific investigation of structures, making molecules easily detectable by mass spectrometry and NMR, and maintaining the physico-chemical properties of the target molecule at the same time. MCE isotope-labeled compounds are all stable isotope-labeled compounds and are non-radioactive labeled substances. MCE isotope-labeled compounds are unique tools for identifying and understanding biological and chemical processes. Stable isotope-labeled products are now getting more and more popular among scientists. The scope of application is gradually penetrating into various scientific fields, such as life sciences, food and medicine, agriculture, environment, geology, etc. Stable isotope-labeled compounds have a wide range of applications in the Life Science areas, such as Metabolomics, Proteomics, Clinical studies, Deuterium drugs, etc.

Isotope-Labeled Compounds Inhibitors (4)

Isotope-Labeled Compounds Related Products (10876):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-W040193S4

DSPC-d₄		99.0%
DSPC-d₄ (1,2-Distearoyl-sn-glycero-3-phosphorylcholine-d₄) is the deuterium labeled DSPC (HY-W040193). DSPC is a cylindrical-shaped lipid. 1,2-Distearoyl-sn-glycero-3-phosphorylcholine is used to synthesize liposomes, and is the lipid component in the lipid nanoparticle (LNP) system.

HY-112870AS

Firmonertinib-d₃ mesylate
Firmonertinib-d₃ (Alflutinib-d₃) mesylate is the deuterium labeled Firmonertinib mesylate (HY-112870A). Firmonertinib (Alflutinib; Furmonertinib) mesylate is is an orally active, mutant-selective, and blood-brain barrier penetrant EGFR inhibitor. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib mesylate has the potential for the research of cancer diseases, especially advanced non-small cell lung cancer (NSCLC) with EGFR ex20ins mutation.

HY-W018171S2

3,5,6-Trichloro-2-pyridinol-¹³C₃
3,5,6-Trichloro-2-pyridinol-¹³C₃ (TCPy-¹³C₃) is the ¹³C-labeled 3,5,6-Trichloro-2-pyridinol (HY-W018171). 3,5,6-Trichloro-2-pyridinol (TCPy) is the main degradation product of the herbicide Triclopyr and the insecticides Chlorpyrifos and Chlorpyrifos-methyl.

HY-45171S

Exatecan intermediate 12-d₅		99.98%
Exatecan intermediate 12-d₅ is the deuterium labeled Exatecan intermediate 12 (HY-45171). Exatecan intermediate 12 is an intermediate for the synthesis of ADC toxin Exatecan (HY-13631) and can be used to prepare ADC compounds.

HY-18085S2

Quercetin-¹³C₃
Quercetin-¹³C₃ is the ¹³C-labeled Quercetin. Quercetin, a natural flavonoid, is a stimulator of recombinant SIRT1 and also a PI3K inhibitor with IC₅₀ of 2.4 μM, 3.0 μM and 5.4 μM for PI3K γ, PI3K δ and PI3K β, respectively.

HY-142283

Dosimertinib-d₃
Dosimertinib-d₃-d₃ is a potent and orally active EGFR inhibitor. Dosimertinib-d₃-d₃ decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₃-d₃ shows antiproliferative and anti-tumor activity. Dosimertinib-d₃-d₃ has the potential for the research of non-small-cell lung cancer (NSCLC).

HY-N11605S

C16(plasm)-18:1(-d₉) PC
C₁₆(plasm)-18:1(d₉) PC (1-(1Z-hexadecenyl)-2-oleoyl(d₉)-sn-glycero-3-phosphocholine) is deuterium labeled PC 16:0/18:1.

HY-B1449S5

Uridine-d₂		99.0%
Uridine-d₂ is the deuterium labeled Uridine.

HY-W654013

Minocycline-d₇
Minocycline-d₇ is deuterium labeled Minocycline. Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.

HY-B1892S1

Cefazolin-¹³C₂,¹⁵N
Cefazolin-¹³C₂,¹⁵N (Cephazolin-¹³C₂,¹⁵N) is ¹³C and ¹⁵N labeled Cefazolin. Cefazolin (Cephazolin) is a first-generation cephalosporin antibiotic and can be used in varieties of bacterial infections research. Cefazolin has anti-inflammatory effect and can attenuate post-operative cognitive dysfunction (POCD).

HY-W008048S

2',3'-O-Isopropylideneadenosine-¹³C₅
2',3'-O-Isopropylideneadenosine-¹³C₅ is the ¹³C-labeled 2',3'-O-Isopropylideneadenosine (HY-W008048). 2',3'-O-Isopropylideneadenosine is a nucleoside compound and also a Golgi-targeting moiety. 2',3'-O-Isopropylideneadenosine constitutes a furanose ribose group that undergoes cyclization at the O (2') and O (3') atoms. As a component of the fluorescent probe TPE-Ade, 2',3'-O-Isopropylideneadenosine enables specific Golgi localization for fluorescence imaging. 2',3'-O-Isopropylideneadenosine participates in the synthesis of aggregation-induced emission (AIE) fluorescent probes.

HY-10195BS

Ruboxistaurin-d₆ hydrochloride
Ruboxistaurin-d₆ (hydrochloride) is the deuterium labeled Ruboxistaurin hydrochloride. Ruboxistaurin (LY333531) hydrochloride is an orally active, selective PKC beta inhibitor (Ki=2 nM). Ruboxistaurin hydrochloride exhibits ATP dependent competitive inhibition of PKC beta I with an IC₅₀ of 4.7 nM. Ruboxistaurin hydrochloride inhibits PKC beta II with an IC₅₀ of 5.9 nM.

HY-B1203S

Fludrocortisone-d₅
Fludrocortisone-d₅ (9α-Fludrocortisone-d₅) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-B0361S1

Aspartame-d₅
Aspartame-d₅ is the deuterium labeled Aspartame. Aspartame (SC-18862) is a methyl ester of a dipeptide. Aspartame can be used as a synthetic nonnutritive sweetener. Aspartame is composed of phenylalanine (50%), aspartic acid (40%) and methanol (10%).

HY-N0683S

2-ambo-Vitamin E-¹³C₆
α-Vitamin E-¹³C₆ is the ¹³C-labeled α-Vitamin E. α-Vitamin E ((+)-α-Tocopherol), a naturally occurring vitamin E form, is a potent antioxidant.

HY-N0168AS

(Rac)-Hesperetin-d₃
(Rac)-Hesperetin-d₃ is the deuterium labeled (Rac)-Hesperetin. (Rac)-Hesperetin is the racemate of Hesperetin (HY-N0168), an orally active multi-target inhibitor. (Rac)-Hesperetin exhibits significant anti-tumor and anti-inflammatory activities by blocking the TGF-β1-mediated Fyn/RhoA signaling axis and the TLR4-MyD88-NF-κB inflammatory pathway. (Rac)-Hesperetin inhibits the formation of actin stress fibers and the migration and invasion of cancer cells, and is suitable for triple-negative breast cancer research. In inflammation models, (Rac)-Hesperetin effectively alleviates lung injury by reducing the release of pro-inflammatory mediators and regulating the activity of oxidative stress enzymes, and is suitable for acute lung injury research. (Rac)-Hesperetin also interferes with the entry and early replication processes of channel catfish virus, inhibits viral gene expression and progeny virus production, thereby protecting cells from virus-induced cytopathic effects.

HY-14946S

Amifampridine-d₃
Amifampridine-d₃ (3,4-Diaminopyridine-d₃) is deuterium labeled Amifampridine. Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (K_v) channel blocker (PCB). Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs). Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research.

HY-B1191S

Nanofin-d₂
Nanofin-d₂ (2,6-Lupetidine-d₂) is the deuterium labeled Nanofin (HY-B1191). Nanofin (2,6-Lupetidine) is a neuro-blocking agent with antihypertensive effects, which can be used for the study of mild to moderate hypertension.

HY-13011S1

Alectinib-d₆		98.05%
Alectinib-d₆ is deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC₅₀ of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC₅₀s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.

HY-B1470S

Azaperone-d₄
Azaperone-d₄ (R-1929-d₄) is the deuterium labeled Azaperone (HY-B1470). Azaperone is an antagonist of dopamine D2 receptor (Dopamine D2 Receptor) and α-adrenergic receptor (AR). Azaperone reduces vasomotor tone, mean arterial pressure, hematocrit, hemoglobin concentration, and etorphine-induced duration; induces transient tachycardia followed by bradycardia, splenic uptake of red blood cells, and sedation; alters animal behaviors; and produces sedation with distinct onset and duration in foals. Azaperone is used for sedation and tranquilization in various animals to reduce stress and aggressive behaviors, and serves as a preanesthetic agent.

Name
Email *

	Sorry, but the email address you supplied was invalid.